Multiplikator Forward P/S Sera Prognostics, Inc. (SERA)

Overcoming the financial deficit and slow test implementation creates a foundation for growth, which is supported by the forward P/S of Sera Prognostics (SERA). Patent protection of algorithms and clinical trials establish a market barrier, while expansion into the US insurance sector defines the development vector. This chart reflects that the 767.60 metric serves as the target capitalization valuation level relative to expected revenue.

Scaling the PreTRM test through B2B contracts with insurers makes Sera Prognostics (SERA) revenue a key driver of capitalization. By analyzing the forward P/S trend, an investor determines the value of one dollar of projected sales, which allows for an assessment of market expectations regarding the expansion into reproductive diagnostics and the classification of the asset by risk level amid excess liquidity.